Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
23
11
2017
accepted:
17
01
2019
entrez:
14
2
2019
pubmed:
14
2
2019
medline:
5
11
2019
Statut:
epublish
Résumé
Treatment with Daratumumab (Dara), a monoclonal anti-CD38 antibody of IgG1 subtype, is effective in patients with multiple myeloma (MM). However, Dara also impairs the cellular immunity, which in turn may lead to higher susceptibility to infections. The exact link between immune impairment and infectious complications is unclear. In this study, we report that nine out of 23 patients (39%) with progressive MM had infectious complications after Dara treatment. Five of these patients had viral infections, two developed with bacterial infections and two with both bacterial and viral infections. Two of the viral infections were exogenous, i.e. acute respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), while five consisted of reactivations, i.e. one herpes simplex (HSV), 1 varicella-zoster (VZV) and three cytomegalovirus (CMV). Infections were solely seen in patients with partial response or worse. Assessment of circulating lymphocytes indicated a selective depletion of NK cells and viral reactivation after Dara treatment, however this finding does not exclude the multiple components of viral immune-surveillance that may get disabled during this monoclonal treatment in this patient cohort. These results suggest that the use of antiviral and antibacterial prophylaxis and screening of the patients should be considered.
Identifiants
pubmed: 30759167
doi: 10.1371/journal.pone.0211927
pii: PONE-D-17-41377
pmc: PMC6374018
doi:
Substances chimiques
Antibodies, Monoclonal
0
daratumumab
4Z63YK6E0E
Banques de données
figshare
['10.6084/m9.figshare.7599350']
Types de publication
Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0211927Déclaration de conflit d'intérêts
Genmab A/S, and Janssen Biotech, commercial companies, provided support by providing free materials for the study. There are no patents, products in development or marketed products to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Références
Clin Exp Immunol. 2016 Aug;185(2):239-51
pubmed: 26940026
Adv Immunol. 2017;133:171-207
pubmed: 28215279
Eur J Cancer. 2016 Nov;67:21-37
pubmed: 27592069
PLoS One. 2011 Feb 17;6(2):e16103
pubmed: 21379581
Blood. 2016 Oct 6;128(14):1821-1828
pubmed: 27531679
Blood. 2011 May 5;117(18):4691-5
pubmed: 21292775
Proc Natl Acad Sci U S A. 2015 Dec 22;112(51):E7128-37
pubmed: 26621750
N Engl J Med. 2015 Aug 13;373(7):621-31
pubmed: 26035255
Blood Adv. 2017 Oct 24;1(23):2105-2114
pubmed: 29296857
J Clin Oncol. 2007 Dec 10;25(35):5616-23
pubmed: 17984186
Br J Haematol. 2016 Aug;174(3):473-7
pubmed: 26455823
Blood. 2016 Jul 21;128(3):384-94
pubmed: 27222480
J Immunol. 2011 Feb 1;186(3):1840-8
pubmed: 21187443
J Am Geriatr Soc. 2005 May;53(5):747-54
pubmed: 15877548
PLoS One. 2011;6(11):e27664
pubmed: 22110712
AIDS Rev. 2017 Apr - Jun;19(2):81-88
pubmed: 28182620
N Engl J Med. 2018 Feb 8;378(6):518-528
pubmed: 29231133
Blood. 2006 Jul 15;108(2):551-8
pubmed: 16537813
PLoS One. 2018 Feb 21;13(2):e0193299
pubmed: 29466462
Eur J Haematol. 2016 Jan;96(1):78-82
pubmed: 25810117
Viruses. 2009 Dec;1(3):979-1002
pubmed: 21994578
Clin Cancer Res. 2018 Aug 15;24(16):4006-4017
pubmed: 29666301
Haematologica. 2015 Jan;100(1):107-13
pubmed: 25344526
Blood. 2016 Jul 7;128(1):37-44
pubmed: 27216216
Ann Intern Med. 1999 Mar 16;130(6):461-70
pubmed: 10075613
N Engl J Med. 2016 Aug 25;375(8):754-66
pubmed: 27557302
Blood. 2004 Dec 1;104(12):3664-71
pubmed: 15304389
Lancet. 2016 Apr 9;387(10027):1551-1560
pubmed: 26778538
Microbes Infect. 2002 Dec;4(15):1545-58
pubmed: 12505527
J Pediatr. 2005 Mar;146(3):423-5
pubmed: 15756234
Front Immunol. 2018 Feb 12;9:183
pubmed: 29483911
Transpl Infect Dis. 2014 Feb;16(1):158-64
pubmed: 24215479
Bone Marrow Transplant. 2008 Aug;42 Suppl 1:S70-S72
pubmed: 18724309
N Engl J Med. 2015 Sep 24;373(13):1207-19
pubmed: 26308596
Sci Rep. 2016 Sep 27;6:34310
pubmed: 27670158
Br J Haematol. 2001 Jun;113(4):1051-9
pubmed: 11442502
J Virol. 2008 Nov;82(21):10820-31
pubmed: 18715907
J Gen Virol. 1985 May;66 ( Pt 5):1087-94
pubmed: 2582081
Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266
pubmed: 11904577
N Engl J Med. 2016 Oct 6;375(14):1319-1331
pubmed: 27705267
Immun Ageing. 2017 May 10;14:10
pubmed: 28491117